Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [3][4]. Group 1: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives materially overstated the company's competitive position [3]. - It is claimed that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. - As a result, statements made by the defendants regarding LifeMD's business and prospects were materially false and misleading [3]. Group 2: Financial Impact - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from a previous guidance of $268 to $275 million [4]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [4]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The deadline to seek the role of lead plaintiff in the federal securities class action against LifeMD is October 27, 2025 [1].

Core Viewpoint - LifeMD, Inc. is facing a class action lawsuit due to alleged securities fraud, with a significant stock price drop following the company's revision of its revenue and EBITDA guidance for 2025 [2][3]. Group 1: Company Performance - On August 5, 2025, LifeMD announced a revision of its full-year 2025 guidance for revenue and adjusted EBITDA due to temporary challenges in its Rex MD business [2]. - Following this announcement, LifeMD's stock price fell by $5.31, or 44.8%, closing at $6.53 per share on August 6, 2025 [2]. Group 2: Allegations in the Lawsuit - The class action complaint alleges that LifeMD's management made materially false and misleading statements regarding the company's business and operations during the class period [3]. - Specific allegations include that the management overstated LifeMD's competitive position and failed to account for rising customer acquisition costs in its RexMD segment [3]. - The lawsuit claims that positive statements made by the management lacked a reasonable basis and were materially misleading [3]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities during the class period are encouraged to file a lead plaintiff motion by October 27, 2025 [4]. - The law firm Glancy Prongay & Murray LLP is leading the class action and is available for inquiries regarding participation [5][6].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook during the specified class period [1][3]. Company Overview - LifeMD, Inc. is a telehealth provider based in New York, offering direct-to-patient virtual care and pharmacy services [2]. Allegations - The lawsuit claims that LifeMD overstated its competitive position and raised its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs like Wegovy and Zepbound [3]. - Following the revelation of the true facts, LifeMD's shares experienced a significant decline of 44%, equating to a drop of $5.31 per share in a single trading session [3]. Investor Information - Investors who acquired LifeMD securities during the class period have until October 27, 2025, to seek appointment as lead plaintiff representative of the class [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in LifeMD to contact them directly to discuss their legal options [1][9]. - A federal securities class action has been filed against LifeMD, with a deadline of October 27, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives materially overstated the company's competitive position and were reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs [6]. - Specific issues cited include the failure to disclose rising customer acquisition costs in the RexMD segment and costs related to obesity treatment drugs [6]. Group 3: Financial Impact - On August 5, 2025, LifeMD revised its revenue guidance, expecting total revenue in the range of $250 to $255 million, down from a previous estimate of $268 to $275 million [7]. - Following this announcement, LifeMD's stock price dropped by 44.8% on August 6, 2025 [7].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its competitive position and financial guidance [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against LifeMD - The complaint alleges that LifeMD misled investors about its competitive position and raised its fiscal year 2025 performance guidance without proper justification [4]. - The company reportedly ignored critical factors such as customer acquisition costs for weight loss drugs, leading to materially misleading public statements throughout the class period [4]. - As a result of the misleading information, investors suffered damages when the truth about LifeMD was revealed [4].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased LifeMD, Inc. (NASDAQ: LFMD) securities between May 7, 2025, and August 5, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Allegations - The complaint asserts that LifeMD's management materially overstated the company's competitive position [2]. - It is claimed that the company was reckless in raising its 2025 guidance without properly accounting for increasing customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - As a result, statements made by the defendants about LifeMD's business operations and prospects were materially false and misleading [2]. Financial Impact - On August 5, 2025, LifeMD revised its full-year 2025 guidance for revenue and adjusted EBITDA due to "temporary challenges" in its RexMD business, which led to a significant stock price drop of $5.31 per share, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by October 27, 2025, and can remain absent class members if they choose not to participate [4]. Company Background - Robbins LLP has been a leader in shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of LifeMD, Inc. securities for the period between May 7, 2025, and August 5, 2025, due to alleged misleading statements and overstatements regarding the company's competitive position and financial guidance [1][5]. Group 1: Lawsuit Details - The lawsuit claims that LifeMD's defendants made materially false and misleading statements, including overstating the company's competitive position and inadequately accounting for rising customer acquisition costs [5]. - Investors who purchased LifeMD securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by October 27, 2025, to represent other class members in the litigation [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in the field [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, due to alleged misleading statements and failure to disclose critical information regarding the company's competitive position and customer acquisition costs [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that LifeMD's defendants made materially false and misleading statements about the company's competitive position and financial guidance, particularly regarding customer acquisition costs in the RexMD segment and the sale of obesity treatment drugs [5]. - Investors who purchased LifeMD securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by October 27, 2025, to represent other class members in the litigation [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly misleading investors about its business prospects and competitive position during a specified period in 2025 [1][2]. Allegations - The complaint alleges that LifeMD's management materially overstated the company's competitive position and recklessly raised its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The statements made by the defendants regarding LifeMD's business operations and prospects were claimed to be materially false and misleading [2]. Financial Impact - Following the announcement of its second quarter 2025 results, which included a revision of full-year guidance due to "temporary challenges" in the RexMD business, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 27, 2025, although they can remain absent class members without taking action [4].

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or “the Company”) (NASDAQ: LFMD) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired LifeMD securities ...